Interfering parameters in the determination of urinary globotriaosylceramide (Gb3) in patients with chronic kidney disease

Journal of Nephrology

Volumn 28, Issue 6, 2015, Pages 679-689

  Gaggl, Martina ^a   Hofer, Marlene ^a   Weidner, Stefanie ^a   Kleinert, Julia ^a   Fauler, Günter ^b   Wallner, Manfred ^c   Kotanko, Peter ^d   Paschke, Eduard ^b   Sunder Plassmann, Gere ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF GRAZ   (Austria)

^c Klinikum Wels Grieskirchen GmbH   (Austria)

^d RENAL RESEARCH INSTITUTE   (United States)

Author keywords

Chronic kidney disease; Fabry disease; Globotriaosylceramide; Lysosomal storage disorder

Indexed keywords

GLOBOTRIAOSYLCERAMIDE; GLYCOLIPID; BIOLOGICAL MARKER; CERAMIDE TRIHEXOSIDE; CREATININE; ISOPROTEIN;

ADULT; ARTICLE; BACTERIURIA; CHRONIC KIDNEY DISEASE; DIABETIC NEPHROPATHY; ELECTROSPRAY MASS SPECTROMETRY; FABRY DISEASE; FEMALE; GLOMERULONEPHRITIS; GLOMERULUS FILTRATION RATE; GLUCOSURIA; HEMATURIA; HUMAN; KIDNEY FUNCTION; KIDNEY POLYCYSTIC DISEASE; LEUKOCYTE; LEUKOCYTURIA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; AGE; AGED; BACTERIAL LOAD; BLOOD; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; CYTOLOGY; MICROBIOLOGY; NAIL PATELLA SYNDROME; NEPHRITIS; PATHOPHYSIOLOGY; SEX DIFFERENCE; URINE;

ADULT; AGE FACTORS; AGED; BACTERIAL LOAD; BIOMARKERS; CREATININE; FABRY DISEASE; FEMALE; HEMATURIA; HUMANS; LEUKOCYTES; MALE; MIDDLE AGED; NAIL-PATELLA SYNDROME; NEPHRITIS, HEREDITARY; PROTEIN ISOFORMS; RENAL INSUFFICIENCY, CHRONIC; SEX FACTORS; TRIHEXOSYLCERAMIDES; URINE;

EID: 84944206899     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: 10.1007/s40620-015-0193-1     Document Type: Article

References (29)

1. Nudelman E, Kannagi R, Hakomori S, Parsons M, Lipinski M, Wiels J, Fellous M, Tursz T (1983) A glycolipid antigen associated with Burkitt lymphoma defined by a monoclonal antibody. Science 220:509–511
2. Fletcher KS, Bremer EG, Schwarting GA (1979) P blood group regulation of glycosphingolipid levels in human erythrocytes. J Biol Chem 254:11196–11198
3. Waddell T, Head S, Petric M, Cohen A, Lingwood C (1988) Globotriosyl ceramide is specifically recognized by the Escherichia coli verocytotoxin 2. Biochem Biophys Res Commun 152:674–679 (pii: S0006-291X(88)80091-3)
4. Lingwood CA, Branch DR (2011) The role of glycosphingolipids in HIV/AIDS. Discov Med 11:303–313
5. Fuller M, Sharp PC, Rozaklis T, Whitfield PD, Blacklock D, Hopwood JJ, Meikle PJ (2005) Urinary lipid profiling for the identification of fabry hemizygotes and heterozygotes. Clin Chem 51:688–694. doi:10.1373/clinchem.2004.041418
6. Mills K, Morris P, Lee P, Vellodi A, Waldek S, Young E, Winchester B (2005) Measurement of urinary CDH and CTH by tandem mass spectrometry in patients hemizygous and heterozygous for Fabry disease. J Inherit Metab Dis 28:35–48. doi:10.1007/s10545-005-5263-4
7. Paschke E, Fauler G, Winkler H, Schlagenhauf A, Plecko B, Erwa W, Breunig F, Urban W, Vujkovac B, Sunder-Plassmann G, Kotanko P (2011) Urinary total globotriaosylceramide and isoforms to identify women with Fabry disease: a diagnostic test study. Am J Kidney Dis 57:673–681. doi:10.1053/j.ajkd.2010.10.046
8. Fauler G, Rechberger GN, Devrnja D, Erwa W, Plecko B, Kotanko P, Breunig F, Paschke E (2005) Rapid determination of urinary globotriaosylceramide isoform profiles by electrospray ionization mass spectrometry using stearoyl-d35-globotriaosylceramide as internal standard. Rapid Commun Mass Spectrom 19:1499–1506. doi:10.1002/rcm.1948
9. An D, Na C, Bielawski J, Hannun YA, Kasper DL (2011) Membrane sphingolipids as essential molecular signals for Bacteroides survival in the intestine. Proc Natl Acad Sci USA 108(Suppl 1):4666–4671. doi:10.1073/pnas.1001501107
10. Kotanko P, Kramar R, Devrnja D, Paschke E, Voigtländer T, Auinger M, Pagliardini S, Spada M, Demmelbauer K, Lorenz M, Hauser AC, Kofler HJ, Lhotta K, Neyer U, Pronai W, Wallner M, Wieser C, Wiesholzer M, Zodl H, Födinger M, Sunder-Plassmann G (2004) Results of a nationwide screening for Anderson-Fabry disease among dialysis patients. J Am Soc Nephrol 15:1323–1329. doi:10.1097/01.ASN.0000124671.61963.1E
11. Aerts JM, Groener JE, Kuiper S, Donker-Koopman WE, Strijland A, Ottenhoff R, van Roomen C, Mirzaian M, Wijburg FA, Linthorst GE, Vedder AC, Rombach SM, Cox-Brinkman J, Somerharju P, Boot RG, Hollak CE, Brady RO, Poorthuis BJ (2008) Elevated globotriaosylsphingosine is a hallmark of Fabry disease. Proc Natl Acad Sci USA 105:2812–2817. doi:10.1073/pnas.0712309105
12. Auray-Blais C, Ntwari A, Clarke JT, Warnock DG, Oliveira JP, Young SP, Millington DS, Bichet DG, Sirrs S, West ML, Casey R, Hwu WL, Keutzer JM, Zhang XK, Gagnon R (2012) How well does urinary lyso-Gb3 function as a biomarker in Fabry disease? Clin Chim Acta 411:1906–1914. doi:10.1016/j.cca.2010.07.038
13. Rombach SM, Dekker N, Bouwman MG, Linthorst GE, Zwinderman AH, Wijburg FA, Kuiper S, Vd Bergh Weerman MA, Groener JE, Poorthuis BJ, Hollak CE, Aerts JM (2010) Plasma globotriaosylsphingosine: diagnostic value and relation to clinical manifestations of Fabry disease. Biochim Biophys Acta 1802:741–748. doi:10.1016/j.bbadis.2010.05.003
14. Auray-Blais C, Boutin M, Gagnon R, Dupont FO, Lavoie P, Clarke JT (2012) Urinary globotriaosylsphingosine-related biomarkers for Fabry disease targeted by metabolomics. Anal Chem 84:2745–2753. doi:10.1021/ac203433e
15. Hozumi I, Nishizawa M, Ariga T, Miyatake T (1990) Biochemical and clinical analysis of accumulated glycolipids in symptomatic heterozygotes of angiokeratoma corporis diffusum (Fabry’s disease) in comparison with hemizygotes. J Lipid Res 31:335–340
16. Schiffmann R, Waldek S, Benigni A, Auray-Blais C (2010) Biomarkers of Fabry disease nephropathy. Clin J Am Soc Nephrol 5:360–364. doi:10.2215/CJN.06090809
17. Vance DE, Sweeley CC (1967) Quantitative determination of the neutral glycosyl ceramides in human blood. J Lipid Res 8:621–630
18. Young E, Mills K, Morris P, Vellodi A, Lee P, Waldek S, Winchester B (2005) Is globotriaosylceramide a useful biomarker in Fabry disease? Acta Paediatr Suppl 94:51–54 (discussion 37–58)
19. Mills K, Johnson A, Winchester B (2002) Synthesis of novel internal standards for the quantitative determination of plasma ceramide trihexoside in Fabry disease by tandem mass spectrometry. FEBS Lett 515:171–176 (pii: S0014579302024912)
20. Dawson G, Kruski AW, Scanu AM (1976) Distribution of glycosphingolipids in the serum lipoproteins of normal human subjects and patients with hypo- and hyperlipidemias. J Lipid Res 17:125–131
21. Vedder AC, Linthorst GE, van Breemen MJ, Groener JE, Bemelman FJ, Strijland A, Mannens MM, Aerts JM, Hollak CE (2007) The Dutch Fabry cohort: diversity of clinical manifestations and Gb3 levels. J Inherit Metab Dis 30:68–78. doi:10.1007/s10545-006-0484-8
22. Durant B, Forni S, Sweetman L, Brignol N, Meng XL, Benjamin ER, Schiffmann R, Shen JS (2011) Sex differences of urinary and kidney globotriaosylceramide and lyso-globotriaosylceramide in Fabry mice. J Lipid Res 52:1742–1746. doi:10.1194/jlr.M017178
23. McCluer RH, Williams MA, Gross SK, Meisler MH (1981) Testosterone effects on the induction and urinary excretion of mouse kidney glycosphingolipids associated with lysosomes. J Biol Chem 256:13112–13120
24. Koshida H, Takeda R, Miyamori I (1998) Lisinopril decreases plasma free testosterone in male hypertensive patients and increases sex hormone binding globulin in female hypertensive patients. Hypertens Res 21:279–282
25. Schiffmann R, Forni S, Swift C, Brignol N, Wu X, Lockhart DJ, Blankenship D, Wang X, Grayburn PA, Taylor MR, Lowes BD, Fuller M, Benjamin ER, Sweetman L (2014) Risk of death in heart disease is associated with elevated urinary globotriaosylceramide. J Am Heart Assoc 3:e000394. doi:10.1161/JAHA.113.000394
26. Kuchar L, Asfaw B, Poupetova H, Honzikova J, Turecek F, Ledvinova J (2013) Direct tandem mass spectrometric profiling of sulfatides in dry urinary samples for screening of metachromatic leukodystrophy. Clin Chim Acta 425:153–159. doi:10.1016/j.cca.2013.06.027
27. Forni S, Fu X, Schiffmann R, Sweetman L (2009) Falsely elevated urinary Gb3 (globotriaosylceramide, CTH, GL3). Mol Genet Metab 97:91. doi:10.1016/j.ymgme.2009.01.011
28. Auray-Blais C, Millington DS, Barr C, Young SP, Mills K, Clarke JT (2009) Gb(3)/creatinine biomarkers for Fabry disease: issues to consider. Mol Genet Metab 97:237. doi:10.1016/j.ymgme.2009.04.006
29. Cable WJ, McCluer RH, Kolodny EH, Ullman MD (1982) Fabry disease: detection of heterozygotes by examination of glycolipids in urinary sediment. Neurology 32:1139–1145